Citations

Clear

6274 citation(s) found for "To, Andrew".

EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA
Huang, Jie , Li, Bryan , Gajjar, Amar , Endersby, Raelene , Wells, Olivia, Wray, Alison, Raleigh, David R. , Stoller, Schuyler , Mueller, Sabine , Bandopadhayay, Pratiti , Fouladi, Maryam , Onar, Arzu, Gottardo, Nicholas G. , Onar‐Thomas, Arzu , Hansford, Jordan R. , Dodgshun, Andrew , Hwang, Eugene , Leary, Sarah , Hoff, Katja von , Kotecha, Rishi S. , Schild, Steven E. , Bouffet, Éric , Huang, Annie

Mayo Clinic

Neuro-Oncology | June 1, 2021 | Volume: 23 | Issue: Supplement_1 | Pages: i6-i6

10.1093/neuonc/noab090.021 Get It

Abstract Background Pineoblastoma (PB) is a rare embryonal brain tumour most often diagnosed in young children. To date, no clinical trials have been conducted specific to pediatric PB. Collaborative studies performed over the past 30 years have included PB in studies accruing for other embryonal tumours, primarily medulloblastoma (MB), but also including the entity formerly known as CNS-PNET and atypical teratoid rhabdoid tumors. Each of these studies have included only a small number of children with PB, making clinical features difficult to interpret and determinants of outcome difficult to ascertain. Patients and Methods Published centrally reviewed series with sufficient treatment and outcome data from North American and Australian cases were pooled. To investigate associations between variables, Fisher’s exact and Wilcoxon-Mann-Whitney tests, and Spearman correlations were used as appropriate. Kaplan-Meier plots, log-rank tests, and Cox proportional hazards models were used in survival analysis. Results We describe a 30-year review of the reported clinical features of PB and a pooled centrally reviewed, cohort analysis of cases (n=178) from the Children’s Oncology Group (COG) (n=82) groups and several published, centrally reviewed institutional series (n=96). We find young children <3 years of age have a dramatically poorer outlook compared to older children (5-year OS 16.2% +/- 5.3% vs 67.3% +/- 5%) confirming new and novel approaches are needed in future clinical trials for this at risk group. Interestingly, male gender was predictive of worse outcome possibly suggestive of gender specific subgroup risks that needs validation in future studies. Assessment of radiation therapy is not possible as the vast majority of children under age three did not receive any form of radiation therapy. Conclusion Given the relative scarcity of this tumor and the emerging data on subgroups of pineoblastoma, prospective, collaborative international studies will be vital to improving the long-term survival of these patients.
Reply to Letter to the Editor regarding “Surgical armamentarium for salvage laryngectomy closure reinforcements”
Hayden, Richard E. , Mullin, David, Patel, Andrew K., Nagel, Thomas H. , Howard, Brittany E. , Hinni, Michael L., Lott, David L., Donald, Carrlene B., Chang, Brent A.

Mayo Clinic

Head & Neck | May 31, 2021 | Volume: 43 | Issue: 8 | Pages: 2559-2559

10.1002/hed.26759 | PMID 34057754 Get It

Optimal Hemodynamics and Risk of Severe Outcomes Post-Left Ventricular Assist Device Implantation
Rosenbaum, Andrew , Ternus, Bradley W., Stulak, John M., Clavell, Alfredo L., Schettle, Sarah D., Behfar, Atta , Jentzer, Jacob C., Rosenbaum, Andrew N , Behfar, Atta , Ternus, Bradley W., Stulak, John M., Clavell, Alfredo L., Schettle, Sarah D., Jentzer, Jacob C.

Mayo Clinic

ASAIO Journal | May 29, 2021 | Volume: 68 | Issue: 3 | Pages: 325-332

10.1097/mat.0000000000001465 | PMID 35213881 Get It

Data on pre-implant hemodynamic optimization before continuous flow left ventricular assist device placement (CF-LVAD) with respect to patient-centered outcomes remain limited. Consecutive patients undergoing CF-LVAD implant between 2007 and 2017 were identified. Hemodynamic variables, trends, and laboratory studies were evaluated pre-LVAD implant in a logistic regression model to identify predictors of the primary composite endpoint: the need for right ventricular assist device therapy, the requirement for hemodialysis at 90 days, and 30-day mortality. Multivariate modeling identified three variables significantly associated with the primary endpoint: right ventricular stroke work index (RVSWI), right atrial pressure (RAP), and blood urea nitrogen (BUN); all immediately pre-LVAD, p < 0.01. Optimal dichotomization points were 500 mmHg*ml*m−2, 12 mmHg, and 40 mg/dL. The three-component model identified an AUC of 0.77 (p < 0.0001) for the composite endpoint. Optimization of 2/3 parameters, 1/3, and 0/3 was associated with odds ratios of 3.5 (95% CI, 1.1−11.7), 7.2 (95% CI, 2.1−24.2), and 20.6 (95% CI, 5.3−80.6), respectively, relative to those patients who were fully optimized (3/3 parameters). The number of optimized parameters was also associated with 1-year overall survival (p = 0.02). Low RVSWI, high RAP, and high BUN were independently associated with adverse outcomes after the CF-LVAD implant, demonstrating a stepwise association with severe postimplant adverse events.
Prior Statin Use and Risk of Mortality and Severe Disease From Coronavirus Disease 2019: A Systematic Review and Meta-analysis
Yetmar, Zachary A. , Chesdachai, Supavit , Kashour, Tarek , Gerberi, Dana , Badley, Andrew D. , Berbari, Elie F. , Tleyjeh, Imad M. , Gerberi, Danielle J , Badley, Andrew D , Berbari, Elie F , Tleyjeh, Imad M , Yetmar, Zachary A , Chesdachai, Supavit , Riaz, Muhammad

Mayo Clinic

Open Forum Infectious Diseases | May 29, 2021 | Volume: 8 | Issue: 7 | Pages: No page available

10.1093/ofid/ofab284 | PMID 34258316 Get It

Abstract Background Statins up-regulate angiotensin-converting enzyme 2, the receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while also exhibiting pleiotropic antiviral, antithrombotic, and anti-inflammatory properties. Uncertainties exist about their effect on the course of SARS-CoV-2 infection. We sought to systematically review the literature and perform a meta-analysis to examine the association between prior statin use and outcomes of patients with coronavirus disease 2019 (COVID-19). Methods We searched Ovid Medline, Web of Science, Scopus, and the preprint server medRxiv from inception to December 2020. We assessed the quality of eligible studies with the Newcastle-Ottawa quality scale. We pooled adjusted relative risk (aRRs) of the association between prior statin use and outcomes of patients with COVID-19 using the DerSimonian-Laird random-effects model and assessed heterogeneity using the I2 index. Results Overall, 19 (16 cohorts and 3 case-control) studies were eligible, with a total of 395 513 patients. Sixteen of 19 studies had low or moderate risk of bias. Among 109 080 patients enrolled in 13 separate studies, prior statin use was associated with a lower risk of mortality (pooled aRR, 0.65 [95% confidence interval {CI}, .56–.77], I2 = 84.1%) and a reduced risk of severe COVID-19 was also observed in 48 110 patients enrolled in 9 studies (pooled aRR, 0.73 [95% CI, .57–.94], I2 = 82.8%), with no evidence of publication bias. Conclusions Cumulative evidence suggests that prior statin use is associated with lower risks of mortality or severe disease in patients with COVID-19. These data support the continued use of statins medications in patients with an indication for lipid-lowering therapy during the COVID-19 pandemic.
GPCR‐mediated YAP/TAZ inactivation in fibroblasts via EPAC1/2, RAP2C, and MAP4K7
Choi, Kyoung Moo , Haak, Andrew J. , Espinosa, Ana M. Diaz , Cummins, Katherine A. , Link, Patrick A. , Aravamudhan, Aja, Tschumperlin, Daniel J. , Diaz Espinosa, Ana M , Tschumperlin, Daniel J , Link, Patrick A , Wood, David K.

Mayo Clinic

Journal of Cellular Physiology | May 28, 2021 | Volume: 236 | Issue: 11 | Pages: 7759-7774

10.1002/jcp.30459 | PMID 34046891 Get It

AbstractYes‐associated protein (YAP) and PDZ‐binding motif (TAZ) have emerged as important regulators of pathologic fibroblast activation in fibrotic diseases. Agonism of Gαs‐coupled G protein coupled receptors (GPCRs) provides an attractive approach to inhibit the nuclear localization and function of YAP and TAZ in fibroblasts that inhibits or reverses their pathological activation. Agonism of the dopamine D1 GPCR has proven effective in preclinical models of lung and liver fibrosis. However, the molecular mechanisms coupling GPCR agonism to YAP and TAZ inactivation in fibroblasts remain incompletely understood. Here, using human lung fibroblasts, we identify critical roles for the cAMP effectors EPAC1/2, the small GTPase RAP2c, and the serine/threonine kinase MAP4K7 as the essential elements in the downstream signaling cascade linking GPCR agonism to LATS1/2‐mediated YAP and TAZ phosphorylation and nuclear exclusion in fibroblasts. We further show that this EPAC/RAP2c/MAP4K7 signaling cascade is essential to the effects of dopamine D1 receptor agonism on reducing fibroblast proliferation, contraction, and extracellular matrix production. Targeted modulation of this cascade in fibroblasts may prove a useful strategy to regulate YAP and TAZ signaling and fibroblast activities central to tissue repair and fibrosis.
OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study
Sands, B E, Hoops, Timothy, Izanec, James , Gao, Long-Long , Gasink, Christopher , Greenspan, Andrew, Allez, Matthieu , Kuehbacher, Tanja, Lewis, James D. , Mihály, E, Scherl, Ellen , Sandborn, William J. , Irving, Peter Miles , Gao, Long-Long , Danese, Silvio , Hanauer, Stephen B. , Jairath, Vipul , Lewis, James D , Loftus, Edward V. , Panaccione, Remo , Щукина, О. Б.

Mayo Clinic

Journal of Crohn's and Colitis | May 27, 2021 | Volume: 15 | Issue: Supplement_1 | Pages: S001-S002

10.1093/ecco-jcc/jjab075.001 Get It

Abstract Background We studied the efficacy and safety of ustekinumab (UST) vs adalimumab (ADA) through 1 year in biologic-naïve patients (pts) with moderate-to-severe Crohn’s disease. Methods SEAVUE was a multicenter, randomized, blinded, parallel-group, active-controlled study in adults with CD Activity Index (CDAI) scores ≥220/≤450. Biologic-naïve pts failing/intolerant to conventional therapy with any size ulcer on baseline (BL) ileocolonoscopy were eligible. Pts were randomized 1:1 to UST (⁓6mg/kg IV at BL then 90mg SC every 8 weeks [Ws]) or ADA (160/80mg SC at BL/W2, then 40mg SC every 2 Ws) per US-approved regimens (no dose modifications). Primary endpoint was clinical remission at W52 (CDAI &lt;150). Major secondary endpoints were corticosteroid-free remission, clinical response (≥100-point CDAI decrease from BL), remission in pt-reported CDAI components (PRO-2 symptom remission: abdominal pain mean daily score ≤1 and stool frequency mean daily score ≤3), and endoscopic remission (SES-CD score ≤3/0 for pts with BL score=3) at W52 and clinical remission at W16. Results 386 pts were randomized to UST or ADA. BL demographics and disease characteristics were balanced between groups and indicative of pts with early, moderate-to-severe CD (median CD duration, 2.58 years; CDAI, 289.5; SES-CD, 8.0). At W52, 65% of UST-treated and 61% of ADA-treated pts achieved clinical remission (Δ=4.0%; 95% CI, -5.5%, 13.5%; p=0.417). Major secondary endpoints, including endoscopic remission, were similar between groups (Table 1), as were remission rates at assessment points through W52. Some other secondary endpoints showed numerical (not statistical) differences between UST and ADA (Table 1). Key safety events are summarized in Table 2. Among UST-treated and ADA-treated pts, 34.0% and 40.5% had infections, 2.6% and 7.2% had serious adverse events (AEs) of worsening CD, and 6.3% and 11.3% had AEs that led to discontinuation (DC) of study drug, respectively. One ADA-treated pt had active pulmonary TB. Injection-site reactions associated with active treatment occurred in 1.0% of UST-treated and 10.3% of ADA-treated pts. Overall, 15.2% of UST-treated and 23.6% of ADA-treated pts DC before W52. Reasons for DC were primarily lack of efficacy (UST, 2.1% vs ADA, 5.1%), AEs (UST, 5.7% vs ADA, 10.7%), and withdrawal of consent (UST, 5.8% vs ADA, 5.1%). Time to treatment DC was longer with UST vs ADA (post hoc analysis). Conclusion Both UST and ADA were highly effective in this population of biologic-naïve pts. Rates of clinical remission at W52 were not statistically significantly different between treatment groups. DC rates were numerically lower for UST. Safety results were consistent with prior experience for both treatments.
A Contemporary Analysis of Urethral Recurrence following Radical Cystectomy
Khanna, Abhinav, Zganjar, Andrew , Lyon, Timothy D. , Shah, Paras , Tollefson, Matthew K. , Karnes, R. Jeffrey , Tarrell, Robert F., Thapa, Prabin , Thompson, R. Houston, Frank, Igor, Boorjian, Stephen A. , Lyon, Timothy, Tarrell, Robert, Lyon, Timothy D

Mayo Clinic

Journal of Urology | May 25, 2021 | Volume: 206 | Issue: 4 | Pages: 970-977

10.1097/ju.0000000000001842 | PMID 34032500 Get It

Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association
Althouse, Andrew D. , Below, Jennifer E , Claggett, Brian , Cox, Nancy J. , Lemos, James A. de , Deo, Rahul C. , Duval, Sue , Hachamovitch, Rory , Kaul, Sanjay , Keith, Scott W. , Teixeira‐Pinto, Armando , Roger, Véronique L. , Below, Jennifer E , Secemsky, Eric A.

Mayo Clinic

Circulation | May 25, 2021 | Volume: 144 | Issue: 4 | Pages: No page available

10.1161/circulationaha.121.055393 | PMID 34032474 Get It

Statistical analyses are a crucial component of the biomedical research process and are necessary to draw inferences from biomedical research data. The application of sound statistical methodology is a prerequisite for publication in the American Heart Association (AHA) journal portfolio. The objective of this document is to summarize key aspects of statistical reporting that might be most relevant to the authors, reviewers, and readership of AHA journals. The AHA Scientific Publication Committee convened a task force to inventory existing statistical standards for publication in biomedical journals and to identify approaches suitable for the AHA journal portfolio. The experts on the task force were selected by the AHA Scientific Publication Committee, who identified 12 key topics that serve as the section headers for this document. For each topic, the members of the writing group identified relevant references and evaluated them as a resource to make the standards summarized herein. Each section was independently reviewed by an expert reviewer who was not part of the task force. Expert reviewers were also permitted to comment on other sections if they chose. Differences of opinion were adjudicated by consensus. The standards presented in this report are intended to serve as a guide for high-quality reporting of statistical analyses methods and results.
Disseminated Blastomycosis Presenting with Spontaneous Coronary Artery Dissection
Sehgal, Rahul , O'Cochlain, D Fearghas, Virata, Andrew, Singh, Gurpreet , Virata, Andrew R, O'Cochlain, D. Fearghas, Singh, Gurpreet

Mayo Clinic

European Journal of Case Reports in Internal Medicine | May 25, 2021 | Volume: 8 | Issue: 4 | Pages: No page available

10.12890/2021_002511 | PMID 33987130 Get It

Spontaneous coronary artery dissection (SCAD) is increasingly recognized as an important cause of acute coronary syndrome (ACS) and myocardial infarction (MI) in individuals with few or no known atherosclerotic risk factors. While systemic autoimmune inflammatory disorders are associated with precipitating SCAD, the role of infection-induced systemic inflammation in SCAD is not well defined. We present the case of a 49-year-old Caucasian woman with ST-elevation myocardial infarction (STEMI) diagnosed as SCAD from a severe systemic inflammatory response related to disseminated blastomycosis. Punch biopsy of a skin lesion and synovial fluid culture confirmed Blastomyces dermatitidis. This case suggests the possibility of systemic infection-induced inflammation as a precipitating factor in SCAD pathogenesis similar to autoimmune inflammatory disorders.
Propofol, Ketamine, and Etomidate as Induction Agents for Intubation and Outcomes in Critically Ill Patients: A Retrospective Cohort Study
Wan, Chun, Hanson, Andrew C. , Schulte, Phillip J. , Dong, Yue , Bauer, Philippe R.

Mayo Clinic

Critical Care Explorations | May 24, 2021 | Volume: 3 | Issue: 5 | Pages: e0435

10.1097/cce.0000000000000435 | PMID 34046636 Get It

IMPORTANCE: Propofol, ketamine, and etomidate are common anesthetic agents for induction of anesthesia in the ICU. The choice between these agents is complex and may not depend solely upon severity of illness. OBJECTIVES: To evaluate the association between the administration of propofol, ketamine, and etomidate and ICU, hospital mortality, and length of stay. DESIGN, SETTING, AND PARTICIPANTS: Retrospective single-center cohort study. ICUs in a tertiary medical center, between January 01, 2012, and December 31, 2017. Critically ill adult patients given a single IV anesthetic for intubation. MAIN OUTCOME AND MEASURES: Primary outcomes were ICU and hospital mortality. Secondary outcomes were ICU- and hospital-free days through 28 days. An inverse probability of treatment weighed approach was used. The propensity score was estimated using a generalized logit model as a function of patient characteristics, admission source, ICU type, readmission status, length of ICU stays prior to intubation, and acute physiology score. Mortality outcomes were assessed with weighted logistic regression and -free days assessed by weighted linear regression with Bonferroni correction for pairwise comparisons. RESULTS: Of 2,673 patients, 36% received propofol, 30% ketamine and 34% etomidate. Overall ICU and hospital mortality were 19% and 29%, respectively. Patients given ketamine had higher odds of ICU mortality (1.45; [95% CI, 1.07–1.94]; p = 0.015) and patients given etomidate had higher odds of ICU mortality (1.87; 1.40–2.49; p < 0.001), hospital mortality (1.43; 1.09–1.86; p = 0.009), and less ICU-free days (–2.10; –3.21 to –1.00; p < 0.001) than those given propofol. Patients given ketamine and etomidate had similar odds of hospital mortality (1.06; 0.80–1.42; p = 0.761) and similar hospital-free days (0.30; –0.81 to 1.40; p = 0.600). CONCLUSIONS AND RELEVANCE: Compared with ketamine and etomidate, propofol was associated with better outcome in critically ill patients undergoing anesthesia for intubation. Even after adjusting for severity of illness prior to intubation, residual confounders cannot be excluded.